Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5745 Induction and Maintenance Study in Ulcerative Colitis
2014-005217-24Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GS-5745 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint for Cohort 1. Started Sep 2015; status: terminated.
02
Drugs
andecaliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2014-005217-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005217-24.